Brekken RA - Search Results

1

The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.

Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, Wong H, Brekken RA. Dineen SP, et al. Among authors: brekken ra. BMC Cancer. 2008 Nov 27;8:352. doi: 10.1186/1471-2407-8-352. BMC Cancer. 2008. PMID: 19038046 Free PMC article.

2

Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null mice.

Bradshaw AD, Reed MJ, Carbon JG, Pinney E, Brekken RA, Sage EH. Bradshaw AD, et al. Among authors: brekken ra. Wound Repair Regen. 2001 Nov-Dec;9(6):522-30. doi: 10.1046/j.1524-475x.2001.00522.x. Wound Repair Regen. 2001. PMID: 11896995

3

Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer.

Fleming JB, Brekken RA. Fleming JB, et al. Among authors: brekken ra. J Cell Biochem. 2003 Oct 15;90(3):492-501. doi: 10.1002/jcb.10644. J Cell Biochem. 2003. PMID: 14523983 Review.

4

Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer.

Holloway SE, Beck AW, Girard L, Jaber MR, Barnett CC Jr, Brekken RA, Fleming JB. Holloway SE, et al. Among authors: brekken ra. J Am Coll Surg. 2005 Mar;200(3):371-7. doi: 10.1016/j.jamcollsurg.2004.10.005. J Am Coll Surg. 2005. PMID: 15737847

5

Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.

Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Fleming JB, et al. Among authors: brekken ra. Mol Cancer Res. 2005 Jul;3(7):413-23. doi: 10.1158/1541-7786.MCR-04-0206. Mol Cancer Res. 2005. PMID: 16046552 Free article.

6

Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice.

Beck AW, Luster TA, Miller AF, Holloway SE, Conner CR, Barnett CC, Thorpe PE, Fleming JB, Brekken RA. Beck AW, et al. Among authors: brekken ra. Int J Cancer. 2006 May 15;118(10):2639-43. doi: 10.1002/ijc.21684. Int J Cancer. 2006. PMID: 16353142

7

Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.

Holloway SE, Beck AW, Shivakumar L, Shih J, Fleming JB, Brekken RA. Holloway SE, et al. Among authors: brekken ra. Ann Surg Oncol. 2006 Aug;13(8):1145-55. doi: 10.1245/ASO.2006.05.049. Epub 2006 Jun 21. Ann Surg Oncol. 2006. PMID: 16791450

8

Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature.

Korpanty G, Carbon JG, Grayburn PA, Fleming JB, Brekken RA. Korpanty G, et al. Among authors: brekken ra. Clin Cancer Res. 2007 Jan 1;13(1):323-30. doi: 10.1158/1078-0432.CCR-06-1313. Clin Cancer Res. 2007. PMID: 17200371

9

Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.

Whitehurst B, Flister MJ, Bagaitkar J, Volk L, Bivens CM, Pickett B, Castro-Rivera E, Brekken RA, Gerard RD, Ran S. Whitehurst B, et al. Among authors: brekken ra. Int J Cancer. 2007 Nov 15;121(10):2181-91. doi: 10.1002/ijc.22937. Int J Cancer. 2007. PMID: 17597103

10

A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity.

Udugamasooriya DG, Dineen SP, Brekken RA, Kodadek T. Udugamasooriya DG, et al. Among authors: brekken ra. J Am Chem Soc. 2008 Apr 30;130(17):5744-52. doi: 10.1021/ja711193x. Epub 2008 Apr 2. J Am Chem Soc. 2008. PMID: 18386897

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

236 results

Search Page

Filters